Bortezomib induces caspase-dependent apoptosis in Hodgkin lymphoma cell lines and is associated with reduced c-FLIP expression: A gene expression profiling study with implications for potential combination therapies

Leukemia Research

Volumn 32, Issue 2, 2008, Pages 275-285

  Zhao, Xiaoxian ^a   Qiu, Wansong ^a   Kung, Jiachun ^a   Zhao, Xinyu ^a   Peng, Xuejun ^b   Yegappan, Mani ^c   Yen Lieberman, Belinda ^a   Hsi, Eric D ^a  

^a Department of Clinical Pathology ^*  (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Apoptosis; Bortezomib; Cancer therapy; cFLIP; Hodgkin lymphoma; Proteasome inhibitor; TRAIL

Indexed keywords

BORTEZOMIB; CASPASE 8; CASPASE INHIBITOR; COMPLEMENTARY DNA; DEATH RECEPTOR 4; DEATH RECEPTOR 5; FLICE INHIBITORY PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN P85; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CLASSICAL HODGKIN LYMPHOMA; CONTROLLED STUDY; DNA MICROARRAY; DRUG EFFECT; DRUG INHIBITION; GENE EXPRESSION; HODGKIN DISEASE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REED STERNBERG CELL; TISSUE MICROARRAY;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; BORONIC ACIDS; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CASPASES; CELL LINE, TUMOR; CELL PROLIFERATION; FLOW CYTOMETRY; GENE EXPRESSION; GENE EXPRESSION PROFILING; HODGKIN DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PYRAZINES; REED-STERNBERG CELLS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TISSUE ARRAY ANALYSIS; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 38949181537     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2007.05.024     Document Type: Article

References (65)

1. Kanzler H., Kuppers R., Hansmann M.L., and Rajewsky K. Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. J Exp Med 184 (1996) 1495-1505
2. Kuppers R., Rajewsky K., Zhao M., et al. Hodgkin disease: Hodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development. Proc Natl Acad Sci USA 91 (1994) 10962-10966
3. Marafioti T., Hummel M., Foss H.D., et al. Hodgkin and Reed-Sternberg cells represent an expansion of a single clone originating from a germinal center B cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription. Blood 95 (2000) 1443-1450
4. Bargou R.C., Emmerich F., Krappmann D., et al. Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest 100 (1997) 2961-2969
5. Emmerich F., Meiser M., Hummel M., et al. Overexpression of I kappa B alpha without inhibition of NF-kappaB activity and mutations in the I kappa B alpha gene in Reed-Sternberg cells. Blood 94 (1999) 3129-3134
6. Izban K.F., Ergin M., Huang Q., et al. Characterization of NF-kappaB expression in Hodgkin's disease: inhibition of constitutively expressed NF-kappaB results in spontaneous caspase-independent apoptosis in Hodgkin and Reed-Sternberg cells. Mod Pathol 14 (2001) 297-310
7. Dalton W.S. The proteasome. Semin Oncol 31 (2004) 3-9
8. Zhou P. Targeted protein degradation. Curr Opin Chem Biol 9 (2005) 51-55
9. Hochstrasser M. Ubiquitin-dependent protein degradation. Annu Rev Genet 30 (1996) 405-439 405-39
10. Pickart C.M. Back to the future with ubiquitin. Cell 116 (2004) 181-190
11. Goldberg A.L., Stein R., and Adams J. New insights into proteasome function: from archaebacteria to drug development. Chem Biol 2 (1995) 503-508
12. King R.W., Deshaies R.J., Peters J.M., and Kirschner M.W. How proteolysis drives the cell cycle. Science 274 (1996) 1652-1659
13. Pham L.V., Tamayo A.T., Yoshimura L.C., Lo P., and Ford R.J. Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol 171 (2003) 88-95
14. Kim Y., Suh N., Sporn M., and Reed J.C. An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis. J Biol Chem 277 (2002) 22320-22329
15. Maki C.G., Huibregtse J.M., and Howley P.M. In vivo ubiquitination and proteasome-mediated degradation of p53(1). Cancer Res 56 (1996) 2649-2654
16. Park D.J., and Lenz H.J. The role of proteasome inhibitors in solid tumors. Ann Med 36 (2004) 296-303
17. Adams J. The proteasome as a novel target for the treatment of breast cancer. Breast Dis 15 (2002) 61-70
18. Anderson K.C. Clinical update: novel targets in multiple myeloma. Semin Oncol 31 (2004) 27-32
19. Cortes J., Thomas D., Koller C., et al. Phase I study of bortezomib in refractory or relapsed acute leukemias. Clin Cancer Res 10 (2004) 3371-3376
20. Kane R.C., Bross P.F., Farrell A.T., and Pazdur R. Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist 8 (2003) 508-513
21. O'Connor O.A. The emerging role of bortezomib in the treatment of indolent non-Hodgkin's and mantle cell lymphomas. Curr Treat Options Oncol 5 (2004) 269-281
22. Reddy K.G. Activity of bortezomib in advanced non-small-cell lung cancer. Clin Lung Cancer 6 (2004) 141-142
23. Schenkein D.P. Use of proteasome inhibition in the treatment of lung cancer. Clin Lung Cancer 6 Suppl. 2 (2004) S89-S96
24. Goy A., Younes A., Mclaughlin P., et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B cell non-Hodgkin's lymphoma. J Clin Oncol 23 (2005) 667-675
25. Kondagunta G.V., Drucker B., Schwartz L., et al. Phase II trial of bortezomib for patients with advanced renal cell carcinoma. J Clin Oncol 22 (2004) 3720-3725
26. O'Connor O.A., Wright J., Moskowitz C., et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 23 (2005) 676-684
27. Papandreou C.N., Daliani D.D., Nix D., et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 22 (2004) 2108-2121
28. Berenson J.R., Ma H.M., and Vescio R. The role of nuclear factor-kappaB in the biology and treatment of multiple myeloma. Semin Oncol 28 (2001) 626-633
29. Jagannath S., Barlogie B., Berenson J., et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 127 (2004) 165-172
30. Richardson P.G., Barlogie B., Berenson J., et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348 (2003) 2609-2617
31. Hideshima T., Chauhan D., Richardson P., et al. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 277 (2002) 16639-16647
32. Traenckner E.B., Wilk S., and Baeuerle P.A. A proteasome inhibitor prevents activation of NF-kappa B and stabilizes a newly phosphorylated form of I kappa B-alpha that is still bound to NF-kappa B. EMBO J 13 (1994) 5433-5441
33. Meriin A.B., Gabai V.L., Yaglom J., Shifrin V.I., and Sherman M.Y. Proteasome inhibitors activate stress kinases and induce Hsp72. Diverse effects on apoptosis. J Biol Chem 273 (1998) 6373-6379
34. Yagita H., Takeda K., Hayakawa Y., Smyth M.J., and Okumura K. TRAIL and its receptors as targets for cancer therapy. Cancer Sci 95 (2004) 777-783
35. Ricci M.S., Jin Z., Dews M., et al. Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity. Mol Cell Biol 24 (2004) 8541-8555
36. Scaffidi C., Schmitz I., Krammer P.H., and Peter M.E. The role of c-FLIP in modulation of CD95-induced apoptosis. J Biol Chem 274 (1999) 1541-1548
37. Kennedy B.J., Fremgen A.M., and Menck H.R. The National Cancer Data Base report on Hodgkin's disease for 1985-1989 and 1990-1994. Cancer 83 (1998) 1041-1047
38. Diehl V., Stein H., Hummel M., Zollinger R., and Connors J.M. Hodgkin's lymphoma: biology and treatment strategies for primary, refractory, and relapsed disease. Hematology (Am Soc Hematol Educ Program) (2003) 225-247
39. Palombella V.J., Rando O.J., Goldberg A.L., and Maniatis T. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell 78 (1994) 773-785
40. Ni H., Ergin M., Huang Q., et al. Analysis of expression of nuclear factor kappa B (NF-kappa B) in multiple myeloma: downregulation of NF-kappa B induces apoptosis. Br J Haematol 115 (2001) 279-286
41. Bargou R.C., Leng C., Krappmann D., et al. High-level nuclear NF-kappa B and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells. Blood 87 (1996) 4340-4347
42. Chawla-Sarkar M., Bae S.I., Reu F.J., et al. Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ 11 (2004) 915-923
43. Sayers T.J., Brooks A.D., Koh C.Y., et al. The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP. Blood 102 (2003) 303-310
44. Sayers T.J., and Murphy W.J. Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy. Cancer Immunol Immunother 55 (2006) 76-84
45. Roue G., Perez-Galan P., Lopez-Guerra M., et al. Selective inhibition of IkappaB kinase sensitizes mantle cell lymphoma B cells to TRAIL by decreasing cellular FLIP level. J Immunol 178 (2007) 1923-1930
46. Dutton A., O'Neil J.D., Milner A.E., et al. Expression of the cellular FLICE-inhibitory protein (c-FLIP) protects Hodgkin's lymphoma cells from autonomous Fas-mediated death. Proc Natl Acad Sci USA 101 (2004) 6611-6616
47. Mathas S., Lietz A., Anagnostopoulos I., et al. c-FLIP mediates resistance of Hodgkin/Reed-Sternberg cells to death receptor-induced apoptosis. J Exp Med 199 (2004) 1041-1052
48. Thomas R.K., Kallenborn A., Wickenhauser C., et al. Constitutive expression of c-FLIP in Hodgkin and Reed-Sternberg cells. Am J Pathol 160 (2002) 1521-1528
49. Uherova P., Olson S., Thompson M.A., Juskevicius R., and Hamilton K.S. Expression of c-FLIP in classic and nodular lymphocyte-predominant Hodgkin lymphoma. Appl Immunohistochem Mol Morphol 12 (2004) 105-110
50. Zheng B., Georgakis G.V., Li Y., et al. Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-kappaB mutations or activation of the CD30, CD40, and RANK receptors. Clin Cancer Res 10 (2004) 3207-3215
51. Alcivar A., Hu S., Tang J., and Yang X. DEDD and DEDD2 associate with caspase-8/10 and signal cell death. Oncogene 22 (2003) 291-297
52. Lee J.C., Schickling O., Stegh A.H., et al. DEDD regulates degradation of intermediate filaments during apoptosis. J Cell Biol 158 (2002) 1051-1066
53. Zhan Y., Hegde R., Srinivasula S.M., Fernandes-Alnemri T., and Alnemri E.S. Death effector domain-containing proteins DEDD and FLAME-3 form nuclear complexes with the TFIIIC102 subunit of human transcription factor IIIC. Cell Death Differ 9 (2002) 439-447
54. Eymin B., Dubrez L., Allouche M., and Solary E. Increased gadd153 messenger RNA level is associated with apoptosis in human leukemic cells treated with etoposide. Cancer Res 57 (1997) 686-695
55. Fontanier-Razzaq N.C., Hay S.M., and Rees W.D. Upregulation of CHOP-10 (gadd153) expression in the mouse blastocyst as a response to stress. Mol Reprod Dev 54 (1999) 326-332
56. DuHadaway J.B., Sakamuro D., Ewert D.L., and Prendergast G.C. Bin1 mediates apoptosis by c-Myc in transformed primary cells. Cancer Res 61 (2001) 3151-3156
57. Ge K., Duhadaway J., Sakamuro D., et al. Losses of the tumor suppressor BIN1 in breast carcinoma are frequent and reflect deficits in programmed cell death capacity. Int J Cancer 85 (2000) 376-383
58. Kissil J.L., Cohen O., Raveh T., and Kimchi A. Structure-function analysis of an evolutionary conserved protein, DAP3, which mediates TNF-alpha- and Fas-induced cell death. EMBO J 18 (1999) 353-362
59. Miyazaki T., and Reed J.C. A GTP-binding adapter protein couples TRAIL receptors to apoptosis-inducing proteins. Nat Immunol 2 (2001) 493-500
60. Miyazaki T., Shen M., Fujikura D., et al. Functional role of death associated protein 3 (DAP3) in anoikis. J Biol Chem (2004)
61. Mukamel Z., and Kimchi A. Death-associated protein 3 localizes to the mitochondria and is involved in the process of mitochondrial fragmentation during cell death. J Biol Chem 279 (2004) 36732-36738
62. Dodson G.E., Shi Y., and Tibbetts R.S. DNA replication defects, spontaneous DNA damage, and ATM-dependent checkpoint activation in replication protein A-deficient cells. J Biol Chem 279 (2004) 34010-34014
63. Panka D.J., Mano T., Suhara T., Walsh K., and Mier J.W. Phosphatidylinositol 3-kinase/Akt activity regulates c-FLIP expression in tumor cells. J Biol Chem 276 (2001) 6893-6896
64. Xiao C., Yang B.F., Song J.H., et al. Inhibition of CaMKII-mediated c-FLIP expression sensitizes malignant melanoma cells to TRAIL-induced apoptosis. Exp Cell Res 304 (2005) 244-255
65. Zeuner A., Pedini F., Signore M., et al. Increased death receptor resistance and FLIPshort expression in polycythemia vera erythroid precursor cells. Blood 107 (2006) 3495-3502